esas for the management of lower-risk mds
Published 3 years ago • 46 plays • Length 2:37Download video MP4
Download video MP3
Similar videos
-
1:48
the impact of esas in lower-risk mds
-
2:04
the role of esas agents in low-risk mds
-
2:25
approaching esa failure in patients with lower-risk mds
-
1:34
managing adverse events with novel therapies in lower-risk mds
-
1:34
perspectives on the management of low and high-risk mds
-
1:20
the current standard of care for patients with lower-risk mds
-
13:39
key highlights in mds: treating lower-risk & higher-risk disease, trial updates, and more
-
11:53
the optimal treatment of lower risk mds
-
6:45
mds survivor: cindy sargeant
-
3:54
life with mds: jill shares how her family helped her overcome an mds diagnosis
-
4:28
understanding myelodysplastic syndromes (mds)
-
0:52
the need to incorporate disease-modifying drugs in lower-risk mds
-
2:12
improving the treatment of low-risk mds: luspatercept, treatment sequencing & disease classification
-
1:45
a phase ii study of elritercept for lower-risk mds
-
2:11
new therapeutic options for low-risk mds
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
1:22
key advances in mds management
-
3:38
a new set of treatment options for low-risk mds
-
0:55
the unmet needs in low-risk mds
-
1:02
emerging treatment options for lower- and higher-risk mds and ongoing trials
-
1:50
considerations for risk-adapted therapy in lower-risk mds
-
6:37
low-risk mds updates from ash19